About the Webinar
Obesity treatments continue to evolve rapidly, creating new opportunities and complex decisions for self-insured plan sponsors. With FDA approval of the first oral GLP-1 therapy for weight loss, along with the expansion of direct-to-consumer platforms, employers are reassessing their coverage strategies. Attendees will hear from Employers Health’s Kevin Wenceslao and Alexis Sova as they utilize Employers Health book of business data to discuss the importance of:
- Defining and documenting your anti-obesity coverage philosophy;
- Monitoring emerging medications and therapies and what they can mean for your population;
- Clearly communicating with members about your organization’s coverage decisions and ensuring they are aware of alternative resources.